Comparing Billiontoone (BLLN) & The Competition

Billiontoone (NASDAQ:BLLN) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it compare to its peers? We will compare Billiontoone to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Billiontoone and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Billiontoone	$305.11 million	$7.45 million	118.59
Billiontoone Competitors	$19.21 billion	$301.67 million	7.03

Billiontoone’s peers have higher revenue and earnings than Billiontoone. Billiontoone is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 50.2% of Billiontoone shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Billiontoone and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1	3	7	0	2.55
Billiontoone Competitors	1871	7744	13372	828	2.55

Billiontoone currently has a consensus target price of $124.38, indicating a potential upside of 14.00%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.25%. Given Billiontoone’s higher probable upside, research analysts clearly believe Billiontoone is more favorable than its peers.

Profitability

This table compares Billiontoone and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Billiontoone	10.95%	9.16%	6.78%
Billiontoone Competitors	-8.06%	-136.93%	-1.64%

Summary

Billiontoone beats its peers on 7 of the 12 factors compared.

Billiontoone Company Profile

BillionToOne is a molecular diagnostics company that develops and provides genetic testing for prenatal care and cancer care. Its tests use the company’s molecular counting technology to detect and measure genetic material in patient samples. In prenatal care, BillionToOne offers screening for chromosomal conditions and certain inherited single-gene disorders. Its UNITY platform includes tests designed to assess fetal risk using a pregnant patient’s blood sample. The company also provides oncology testing, including services designed to help characterize tumors and detect cancer-related genetic material.